Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Byrd, J. C.
2899  Ergebnisse:
Personensuche X
?
1

Characterization of Mechanisms of Resistance in Previously ..:

Woyach, J. A. ; Jones, D. ; Jurczak, W....
Hematological Oncology.  41 (2023)  S2 - p. 249-250 , 2023
Link: https://doi.org/10.1002/..
 
?
2

Updated follow‐up of BELLWAVE‐001: an open‐label, single‐ar..:

Eradat, H. ; Woyach, J. ; Flinn, I. W....
Hematological Oncology.  41 (2023)  S2 - p. 565-567 , 2023
Link: https://doi.org/10.1002/..
 
?
3

Efficacy of Red Cell Salvage Systems in Open Acetabular Sur..:

MacDonald, S. ; Byrd, C. ; Barlow, E....
Advances in Orthopedics.  2022 (2022)  - p. 1-6 , 2022
Link: https://doi.org/10.1155/..
 
?
4

P525: PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED..:

Byrd, J. C. ; Cortes, J. E. ; Minden, M. D....
HemaSphere.  6 (2022)  - p. 424-425 , 2022
Link: https://doi.org/10.1097/..
 
?
5

P682: NEMTABRUTINIB (MK-1026), A NON-COVALENT INHIBITOR OF ..:

Woyach, J. ; Flinn, I. W. ; Awan, F. T....
HemaSphere.  6 (2022)  - p. 578-579 , 2022
Link: https://doi.org/10.1097/..
 
?
6

FIRST RESULTS OF A HEAD‐TO‐HEAD TRIAL OF ACALABRUTINIB VERS..:

Hillmen, P. ; Byrd, J. C. ; Ghia, P....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
7

CN4 Patient-Reported Outcomes from the Phase 3, Randomized ..:

Walker, P. ; Sharman, J.P. ; Jurczak, W....
Value in Health.  24 (2021)  - p. S3-S4 , 2021
Link: https://doi.org/10.1016/..
 
?
8

Nonlinear analysis of heart rate variability for evaluating..:

Byrd, C.J. ; Johnson, J.S. ; Radcliffe, J.S....
Animal.  14 (2020)  2 - p. 379-387 , 2020
Link: https://doi.org/10.1017/..
 
?
9

PRO71 THE HUMANISTIC BURDEN OF GLYCOGEN STORAGE DISEASE TYP..:

Butler, J. ; Dress, A. ; Theodore-Oklota, C....
Value in Health.  23 (2020)  - p. S341 , 2020
Link: https://doi.org/10.1016/..
 
?
10

Acalabrutinib With Obinutuzumab in Treatment‐Naive and Rela..:

Woyach, J. ; Rogers, K.A. ; Bhat, S....
Hematological Oncology.  37 (2019)  S2 - p. 209-210 , 2019
Link: https://doi.org/10.1002/..
 
?
11

229 Can baseline heart rate variability be used as a predic..:

Byrd, C ; Lay, D
Journal of Animal Science.  96 (2018)  suppl_3 - p. 9-9 , 2018
Link: https://doi.org/10.1093/..
 
?
12

Leukemia-cell proliferation and disease progression in pati..:

Murphy, E J ; Neuberg, D S ; Rassenti, L Z...
Leukemia.  31 (2017)  6 - p. 1348-1354 , 2017
Link: https://doi.org/10.1038/..
 
?
13

Extended follow-up and impact of high-risk prognostic facto..:

Brown, J R ; Hillmen, P ; O'Brien, S...
Leukemia.  32 (2017)  1 - p. 83-91 , 2017
Link: https://doi.org/10.1038/..
 
?
14

The mutational oncoprint of recurrent cytogenetic abnormali..:

Eisfeld, A-K ; Mrózek, K ; Kohlschmidt, J...
Leukemia.  31 (2017)  10 - p. 2211-2218 , 2017
Link: https://doi.org/10.1038/..
 
?
15

EFFECT OF SINGLE‐AGENT IBRUTINIB ON TUMOR DEBULKING AND RED..:

Tam, C.S. ; Byrd, J.C. ; O'Brien, S....
Hematological Oncology.  35 (2017)  S2 - p. 233-234 , 2017
Link: https://doi.org/10.1002/..
 
1-15